Education
About Us
Working with TipRanks
Follow Us
D.Western Therapeutics Institute, Inc. (DE:6DW)
FRANKFURT:6DW
6DW Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.27 - €1.37
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€34.62M
Enterprise Value€15.99B
Total Cash (Recent Filing)€1.13B
Total Debt (Recent Filing)¥797.98M
Price to Earnings (P/E)―
Beta-0.93
Next Earnings
Aug 12, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding45,741,512
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)12.24
Price to Sales (P/S)0.00
P/FCF Ratio97.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
D.Western Therapeutics Institute News
PremiumCompany Announcements
D.Western Therapeutics Institute Reports First Quarter Financial Results
PremiumCompany Announcements
D.Western Therapeutics Extends Cataract Research Partnership
PremiumCompany Announcements
D.Western Therapeutics Secures Macau Patent for Diagnostic AgentPremiumCompany Announcements
DWTI Showcases Promising H-1337 Trial Results at ARVO 2025
PremiumCompany Announcements
D.Western Therapeutics Partners with Mie University for Drug Development
PremiumCompany Announcements
FDA Accepts NDA for DWTI’s Novel Lidocaine Patch6DW FAQ
What was D.Western Therapeutics Institute, Inc.’s price range in the past 12 months?
D.Western Therapeutics Institute, Inc. lowest stock price was €0.27 and its highest was €1.37 in the past 12 months.
What is D.Western Therapeutics Institute, Inc.’s market cap?
D.Western Therapeutics Institute, Inc.’s market cap is €34.62M.
When is D.Western Therapeutics Institute, Inc.’s upcoming earnings report date?
D.Western Therapeutics Institute, Inc.’s upcoming earnings report date is Aug 12, 2025 which is in 57 days.
How were D.Western Therapeutics Institute, Inc.’s earnings last quarter?
D.Western Therapeutics Institute, Inc. released its earnings results on May 15, 2025. The company reported -€0.021 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.021.
Is D.Western Therapeutics Institute, Inc. overvalued?
According to Wall Street analysts D.Western Therapeutics Institute, Inc.’s price is currently Overvalued.
Does D.Western Therapeutics Institute, Inc. pay dividends?
D.Western Therapeutics Institute, Inc. does not currently pay dividends.
What is D.Western Therapeutics Institute, Inc.’s EPS estimate?
D.Western Therapeutics Institute, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does D.Western Therapeutics Institute, Inc. have?
D.Western Therapeutics Institute, Inc. has 45,741,512 shares outstanding.
What happened to D.Western Therapeutics Institute, Inc.’s price movement after its last earnings report?
D.Western Therapeutics Institute, Inc. reported an EPS of -€0.021 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of D.Western Therapeutics Institute, Inc.?
Currently, no hedge funds are holding shares in DE:6DW
Company Description
D.Western Therapeutics Institute, Inc.
D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. The company offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; DWR-2206, a regenerative medicine cell-product for bullous keratopathy; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. It is also developing DW-5LBT, a lidocaine patch for neuropathic pain after shingles; K-321 to treat fuch endothelial corneal dystrophy which is in Phase III clinical trials; and H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension. The company was founded in 1999 and is headquartered in Nagoya, Japan.
Technical Analysis
OncoTherapy Science
―
Immuno-Biological Laboratories Co., Ltd.
―
Delta-Fly Pharma, Inc.
―
FunPep Company Limited
―
Kringle Pharma, Inc.
―